Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CRHR1 | P34998 | 7/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12860226 | 0.93 | CYP1A2 (0.44) | CA12CA1CA2CA4CA7 | |
| SCHEMBL1573613 | 0.89 | CYP1A2 (0.47) | CA12CA1CA2CA4CA7 | |
| SCHEMBL11923822 | 0.85 | ALDH1A1 (0.47) | CA12CA1CA2CA4CA7 | |
| SCHEMBL11133752 | 0.83 | CA1 (0.50) | CA12CA1CA2CA4CA7 | |
| SCHEMBL9353842 | 0.82 | CA12 (0.44) | CA12CA1CA2CA4CA7 | |
| SCHEMBL5470095 | 0.82 | CA1 (0.44) | CA12CA1CA2CA4CA7 | |
| SCHEMBL11808509 | 0.82 | CA1 (0.44) | CA12CA1CA2CA4CA7 | |
| SCHEMBL9763218 | 0.82 | CA1 (0.44) | CA12CA1CA2CA4CA7 | |
| SCHEMBL3779042 | 0.82 | CA1 (0.44) | CA12CA1CA2CA4CA7 | |
| Bromide SCHEMBL11808501 | 0.81 | CA1 (0.43) | CA12CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160106742-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. | 2016-04-21 | — | — | US | disclosed |
| US-4732991-A | Substituted phthalides | HILTON DAVIS CHEMICAL CO. (US) | 1988-03-22 | — | — | US | disclosed |
| US-4595768-A | 3-(substituted phenyl)phthalides | THE HILTON-DAVIS CHEMICAL CO. (US) | 1986-06-17 | — | — | US | disclosed |
| US-4494989-A | PRESSURE SENSITIVE CARBONLESS DUPLICATING OR THERMAL MARKING SYSTEMS | THE HILTON-DAVIS CHEMICAL CO. (US) | 1985-01-22 | — | — | US | disclosed |
| US-4351768-A | CARBONLESS, DUPLICATION, INDOLE DYES | STERLING DRUG INC. (US) | 1982-09-28 | — | — | US | disclosed |
| US-4322352-A | Indolyl phthalide compounds | STERLING DRUG INC. (US) | 1982-03-30 | — | — | US | disclosed |
| US-4307018-A | CHROMOGENS FOR COPYING SYSTEMS | STERLING DRUG INC. (US) | 1981-12-22 | — | — | US | disclosed |
| US-4257954-A | INDOLYL-PHENYLSULFONYL-PHENYL METHANE | STERLING DRUG INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4251446-A | COLOR PRECURSORS | STERLING DRUG INC. (US) | 1981-02-17 | — | — | US | disclosed |
| US-4189171-A | PRESSURE SENSITIVE, THERMAL AND HECTOGRAPHIC SYSTEMS | STERLING DRUG INC. (US) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106742-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | PCK1, PDK3, PDK2 | CA12 3371/4885CA1 3928/4885CA2 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.